These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 36316121)
1. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome. Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome. Wang M; Chen P; Li D; Zhao M Mol Biol Rep; 2024 Sep; 51(1):985. PubMed ID: 39278886 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and characteristics of patients with Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252 [TBL] [Abstract][Full Text] [Related]
4. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985 [TBL] [Abstract][Full Text] [Related]
5. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome. Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803 [TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of patients with myelodysplastic syndrome with a bone marrow nucleated erythroid cell proportion of greater than or equal to 50]. Zeng YP; Li B; Qin TJ; Xu ZF; Qu SJ; Pan LJ; Gao QY; Jiao M; Wu JY; Wang HJ; Li CW; Ja YJ; Sun Q; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):651-659. PubMed ID: 39231769 [No Abstract] [Full Text] [Related]
7. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts]. Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134 [No Abstract] [Full Text] [Related]
8. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome. Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737 [TBL] [Abstract][Full Text] [Related]
10. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621 [TBL] [Abstract][Full Text] [Related]
11. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]. Huang HJ; Li B; Qin TJ; Xu ZF; Hu NB; Pan LJ; Qu SQ; Liu D; Zhang YD; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):723-730. PubMed ID: 33113603 [No Abstract] [Full Text] [Related]
12. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis]. Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918 [TBL] [Abstract][Full Text] [Related]
13. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes. Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030 [TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation. Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595 [No Abstract] [Full Text] [Related]
15. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430 [TBL] [Abstract][Full Text] [Related]
16. [Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with Chen Y; Ji YR; Zhang JY; Qin WW; Liu CC; Liu L; Yan XQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1173-1180. PubMed ID: 39192415 [TBL] [Abstract][Full Text] [Related]
17. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281 [TBL] [Abstract][Full Text] [Related]
18. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. GenoMed4All consortium Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542 [TBL] [Abstract][Full Text] [Related]
19. Mutations of myelodysplastic syndromes (MDS): An update. Ganguly BB; Kadam NN Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316 [TBL] [Abstract][Full Text] [Related]
20. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Yang L; Wei X; Gong Y Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]